In Cell Therapy, The Small Things Make a Big Difference

We’ve partnered with industry leaders in cell therapy to reveal differences between CAR-T Non-Responders (NR) in lymphoma versus Responders (R) from the cell therapy product itself.


The proof is in the data. Preview it below, then fill out this form to access the full data set directly in your inbox.

Reveal which subtle gene edits create potent immune cells to reveal therapeutic insight

Researchers used the IsoPlexis system to identify differences from subtle gene edits to Natural Killer cells, detecting critical functional differences that revealed therapeutic choice and correlated with in-vivo mouse activity. Key findings:

  • IsoPlexis’ systems detected critical differences in the impact of subtle gene edits to NK-cell cellular therapies
  • PSI revealed the immune & cytokine production impact of the CRISPR edits to the NK cell therapy of the Cytokine-inducible SH2-containing protein (CIS)
  • The subtle differences detected on IsoPlexis’ platform indicated the preference for gene knockout that correlated to in-vivo activity in mice

Citation: Zhu H, et al. ASH Annual Meeting 2018.



Optimize the quality of cell therapies in bioprocessing

Researchers used the IsoPlexis system to detect outcomes of process changes to cell therapies, and in particular, recognized potency gains from a modified method (MM) versus an original processing method (OM). Key findings:

  • Identified cytokine mechanism of bispecific CD 19 /22 CAR -T cell product potency, across manufacturing methods
  • Uniquely revealed impact on the potency of the updated method for engineered T-cell bioprocessing with PSI™
  • Demonstrated that the Modified Method of CD19 /CD22 Bispecific CAR T-cell manufacturing led to a more consistent polyfunctional response

Citation: Srivastava SK, et al. ASH Annual Meeting 2018.



Predict responders and non-responders from pre-infusion CAR-T product

As published in the journal “Blood”, researchers used the IsoPlexis system to stratify patient responders and non-responders to CAR-T therapy in Non-Hodgkins lymphoma, directly from the pre-infusion product, using IsoPlexis’ unique Polyfunctional Strength Index (PSI).  Key findings:

  • Preinfusion CAR product T-cell subsets with a high polyfunctional profile, i.e. large degree of single-cell cytokine potency, associates significantly with clinical outcome
  • Existing technologies used traditionally for potency were unable to detect these associations in the CAR-T product, in a side by side study
  • PSI of the product was associated with the Objective Response, highlighting the ability to use such metrics in a variety of contexts for optimizing Cell Therapy development

Citation: Rossi J, et al. Blood. 2018.



“They have showed that by using single-cell analyses, heterogeneity may actually improve clinical outcomes.”

- Blood Commentary

© 2019 ISOPLEXIS / All Rights Reserved. For research only. Not for use in diagnostic